Men with BRCA2 mutations located in the central region of the gene (c.2831–c.6401; ovarian cancer cluster region [OCCR], wide definition [2], [22]; see Supplementary material online) had a significantly lower risk of PCa than men with mutations outside this region (HR 0.37, 95% CI 0.14–0.96). The gene discussed is BRCA2; the disease is ovarian cancer.